Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HS-20197 in Advanced Solid Tumors
NCT07834359Phase 1Not yet recruiting
- Sponsor
- Hansoh Pharmaceutical Group
- Start
- Oct 2026
- Primary completion
- Jan 2029
- Countries
- 1
01
Overview
Phase 1, open-label trial of HS-20197 in solid tumor (2 arms), sponsored by Hansoh Pharmaceutical Group. Primary endpoints: Maximum Tolerated Dose at 21 days and Recommended Dose for Expansion at 90 days. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
HS-20197
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT07834359.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07834359.